Death and Venous Thromboembolism Analyses among Hospitalized COVID-19-Positive Patients: A Multicenter Study

Asma Alshahrani1, Abdullah Almoahzieie2,3, Hanan Alshareef4

  • 1Department of Clinical Pharmacy, Faculty of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.

PubMed

Insights

Hospitalized COVID-19 patients face a significant mortality risk and a high incidence of venous thromboembolism (VTE), particularly those with cancer. Close monitoring for VTE is crucial in high-risk individuals.

Area of Science:

  • Internal Medicine
  • Infectious Diseases
  • Cardiology

Background:

  • Coagulation disorders are common in coronavirus disease 2019 (COVID-19) patients, especially those with severe symptoms.
  • Hospitalized COVID-19 patients exhibit increased risks for thrombotic events.
  • Understanding mortality and venous thromboembolism (VTE) in COVID-19 is critical.

Purpose of the Study:

  • To determine the mortality rate in hospitalized COVID-19 patients.
  • To establish the incidence of VTE in this population.
  • To identify risk factors associated with VTE in COVID-19.

Main Methods:

  • Retrospective observational cohort study.
  • Inclusion of adult patients with laboratory-confirmed COVID-19.
  • Multivariate logistic regression analysis to identify VTE predictors.

Main Results:

  • 10.7% of 1024 COVID-19 patients died; 5.7% developed VTE.
  • Mortality was higher in patients over 50, in the ICU, and on mechanical ventilation.
  • Cancer patients had a significantly higher risk of VTE (aOR=2.614, p=0.039).

Conclusions:

  • Hospitalized COVID-19 patients have a substantial mortality rate and VTE prevalence, particularly those with cancer.
  • Anticoagulation therapy may not fully mitigate VTE risk in all COVID-19 patients.
  • Vigilant monitoring for VTE is recommended for high-risk COVID-19 patients.
Abstract